Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Disease 1

Interventions

Docetaxel 276 Prednisone 236 enzalutamide 173 Leuprolide 172 Radiotherapy 164 Abiraterone Acetate 153 Magnetic Resonance Spectroscopy 147 bicalutamide 136 Goserelin 134 Androgen Antagonists 109 Radiosurgery 101 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100 apalutamide 77 gallium 68 PSMA-11 74 abiraterone 74 Specimen Handling 67 Gonadotropin-Releasing Hormone 57 darolutamide 56 Radiation 56 Triptorelin Pamoate 53 cabazitaxel 49 Zoledronic Acid 49 pembrolizumab 48 Flutamide 47 luprolide acetate gel depot 46 Radiotherapy, Intensity-Modulated 46 Brachytherapy 46 Standard of Care 45 Carboplatin 45 Estramustine 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡